BACKGROUND
Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes that recognize riboflavin-derived metabolites presented by the monomorphic major histocompatibility complex (MHC)-class I-related molecule MR1. MAIT cells are highly enriched in the human liver and are increasingly implicated in liver...
Yan-Ruide Li, Xin-Yuan Shen, Yi-Chen Zhu et al.· i Medicina· 0 citations
CD16HSC-NKT cells are established as a versatile and scalable cellular platform that synergizes with cusatuzumab to enhance therapeutic efficacy against RCC, and represent a promising approach to overcoming current limitations of monoclonal antibody therapy and advancing next-generation immunotherapies for solid tumors...
Yan-Ruide Li, Yi-Chen Zhu, Yu-Ning Chen et al.· The Oncologist· 0 citations
HSPC-derived AlloESO-T cells are established as an off-the-shelf, mono-specific cytotoxic T cell therapy with scalable manufacturing, enhanced efficacy, and improved safety, which support broad applicability of AlloESO-T cells across solid tumors.
Yi-Chen Zhu, Jia-Ji Yu, Y. J. Kim et al.· Cell Reports Medicine· 0 citations
HSPC-engineered allogeneic CAR-NKT cells are established as a promising, scalable, and safer immunotherapy platform for MS, supporting their advancement toward clinical translation.
Highlights from the 2026 American Association for Cancer Research Annual Meeting demonstrate significant advances in ADC design, including dual- and multi-payload constructs, multispecific targeting strategies, and immunostimulatory payloads, with the potential to improve clinical outcomes across diverse cancer types.
